<DOC>
	<DOC>NCT00495677</DOC>
	<brief_summary>To assess the viral load response, safety, tolerability and pharmacokinetics of multiple oral doses of PF 00232798 in HIV-positive patient volunteers.</brief_summary>
	<brief_title>A Phase 2 Study Of PF-00232798 In HIV Positive Patients</brief_title>
	<detailed_description />
	<criteria>Asymptomatic HIV1 infected male patients between the ages of 18 and 55 years inclusive. Patients with CCR5 tropic virus as determined by the Monogram PhenoSense Entry assay. Patients who have received any experimental drug within the past four months (prior to the first dosing day of the study) or who have previously received another CCR5 antagonist. Patients with evidence of decompensated liver disease.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Treatment Experienced</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>